Griffin Securities Initiates Ligand Pharma at Buy, $18 PT

Symbols: LGND
Share

Griffin Securities has initiated coverage on Ligand Pharmaceuticals (NASDAQ: LGND) with a Buy rating and $18 price target.


 
 
< Previous
Compass Point Initiates RLJ Lodging Trust at Buy, $18 PT
Next >
Brean Murray Downgrades Pharmasset to Hold, Removes PT
Share
Printer-friendly version
Send to friend
We're Loving

Benzinga's Premium Memberships

Benzinga's News Delivered Free

Brain Trust